We are pleased to be presenting our first analysis from the ABCD Semaglutide audit at the American Diabetes Association Scientific Session virtual session this weekend.
Our real-world cohort was heavier with higher baseline HbA1c levels than those in clinical trials. We demonstrated significant reductions in HbA1c and weight following commencement of semaglutide with mean changes in HbA1c -1.2% (95% CI -1.1, -1.3) or -13.2mmol/mol (95% CI -11.8, -14.5) (P<0.0001), weight of -4.6kg (95% CI -3.9, -5.2; P<0.0001) and BMI -1.5kg/m2 (95% CI -1.3, -1.7, P<0.0001) across the population as a whole. Most interestingly, further reductions in HbA1c and weight occurred when switching from another GLP1-RA to semaglutide, although somewhat attenuated compared to the GLP1-RA naïve group.
As we have done with previous audits all contributors will be acknowledged in all papers and presentations from the audit data and biggest contributors will be offered the possibility of being co-authors. We really appreciate the data submitted by all contributors and look forward to sharing further valuable real-world insights in due course!
With best wishes on behalf of ABCD
Dr Tom Crabtree, ABCD research fellow
Dr Bob Ryder, Clinical lead ABCD audits programme
